

# Angelika Batorova

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7452467/angelika-batorova-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29  
papers

651  
citations

12  
h-index

25  
g-index

32  
ext. papers

720  
ext. citations

3.7  
avg, IF

3.3  
L-index

#	Paper	IF	Citations
29	Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 93, 481-7	7	176
28	Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. <i>British Journal of Haematology</i> , <b>2000</b> , 110, 715-20	4.5	94
27	Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation - the surgical STER. <i>British Journal of Haematology</i> , <b>2011</b> , 152, 340-6	4.5	57
26	The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. <i>Haemophilia</i> , <b>2019</b> , 25, 676-684	3.3	47
25	Rare bleeding disorders. <i>Haemophilia</i> , <b>2012</b> , 18 Suppl 4, 148-53	3.3	45
24	Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 238-47	7	37
23	Increased transgene integration efficiency upon microinjection of DNA into both pronuclei of rabbit embryos. <i>Transgenic Research</i> , <b>2005</b> , 14, 417-28	3.3	33
22	Continuous infusion of coagulation factors: current opinion. <i>Current Opinion in Hematology</i> , <b>2006</b> , 13, 308-15	3.3	31
21	Challenges in the management of hemophilia B with inhibitor. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2013</b> , 39, 767-71	5.3	22
20	Coagulation factor VII variants resistant to inhibitory antibodies. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 972-80	7	17
19	Evaluation of factor V mRNA to define the residual factor V expression levels in severe factor V deficiency. <i>Haematologica</i> , <b>2008</b> , 93, 477-8	6.6	15
18	Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients. <i>Thrombosis Research</i> , <b>2011</b> , 127, 247-53	8.2	13
17	Can we predict clinical cardiotoxicity with cardiac biomarkers in patients after haematopoietic stem cell transplantation?. <i>Cardiovascular Toxicology</i> , <b>2015</b> , 15, 210-6	3.4	12
16	Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 424-5	7	11
15	Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2016</b> , 42, 550-62	5.3	10
14	Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2017</b> , 23, 518-531	3.3	7
13	An unusual reason for obstructive sleep apnea in a boy with hemophilia B: supraglottic papilloma. <i>International Journal of Pediatric Otorhinolaryngology</i> , <b>1996</b> , 34, 165-9	1.7	6

12	At Disease Presentation, Severity of the Bleeding Symptom Predicts the Following Bleeds in Patients with FVII Deficiency. <i>Blood</i> , <b>2011</b> , 118, 30-30	2.2	5
11	Factor V Leiden mutation and its impact on pregnancy complications. <i>Acta Medica (Hradec Kralove)</i> , <b>2011</b> , 54, 117-21	0.8	3
10	Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia. <i>Neoplasma</i> , <b>2021</b> , 68, 626-630	3.3	3
9	Congenital Factor VII Deficiency <b>2014</b> , 413-420		2
8	Real-World Early Treatment with Room Temperature-Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7IPost Hoc Analyses. <i>TH Open</i> , <b>2017</b> , 1, e130-e138	2.7	1
7	Pharmacokinetics of Factor VII. <i>Blood</i> , <b>2011</b> , 118, 2259-2259	2.2	1
6	Gynaecological issues in women with bleeding disorders: CSL Behring Symposium. <i>The Journal of Haemophilia Practice</i> , <b>2019</b> , 6, 28-38	0.2	1
5	Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study. <i>TH Open</i> , <b>2022</b> , 06, e124-e134	2.7	0
4	Continuous Infusion of Coagulation Products in Hemophilia <b>2014</b> , 204-212		
3	Continuous Infusion of Coagulation Products in Hemophilia <b>2010</b> , 44-51		
2	Genetic and Phenotypic Analysis of Families with Inherited Hypo- and Dys-Fibrinogenemia. Fibrinogen Bratislava.. <i>Blood</i> , <b>2005</b> , 106, 1794-1794	2.2	
1	The Factor VII Variant p.A354V-p.P464Hfs: Clinical versus Intracellular and Biochemical Phenotypes Induced by Chemical Chaperones. <i>Applied Sciences (Switzerland)</i> , <b>2021</b> , 11, 5762	2.6	